The U.S. Supreme Court has decided against granting Pfizer's appeal of a $142 million award in favor of Kaiser Foundation's health plan and hospitals regarding the off-label marketing of the Neurontin epilepsy drug, Bloomberg Businessweek reports. The Supreme Court's action also means that a national class action can proceed in which insurance companies, union funds and employers are suing for paying for coverage of "ineffective dosages of Neurontin" on the basis of aggregate data showing a correlation between Pfizer's off-label marketing and the number of off-label prescriptions, Bloomberg Businessweek further reports.
Lawyer and Legal Journalist
